Tech Company Financing Transactions
EnVivo Pharmaceuticals Funding Round
F-Prime Capital joined a $23 million Series B funding round for EnVivo Pharmaceuticals. The round was announced on 11/9/2004.
Transaction Overview
Company Name
Announced On
11/9/2004
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series B
Investors
F-Prime Capital (Lead Investor) (Jason Rhodes)
Proceeds Purpose
EnVivo plans to use the new round of funding to further advance identifying and characterizing novel compounds that may be effective as new treatments for neurodegenerative diseases such as Huntington's and Alzheimer's diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Arsenal St.
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders. CNS disorders account for more hospitalizations, long-term care, and chronic suffering than nearly all other diseases combined.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Deborah Dunsire
Chief Medical Officer
Dana Hilt
Chief Scientific Officer
Gerhard Koenig
VP - Bus. Development
Chris Burnley
VP - General Counsel
Maiken Keson-Brookes
VP - Human Resources
Elaine Ouellette
Browse more venture capital transactions:
Prev: 11/9/2004: VistaPrint venture capital transaction
Next: 11/9/2004: Onset Technology venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs